Braveheart Bio, Inc. (BRVE) Insider Trading
Directors, officers and holders of more than 10% of BRVE report their trades in its stock on SEC Form 4, within two business days. Each row below is one Form 4 transaction line. The one-letter code says what kind of transaction it was: only P (purchase) and S (sale) are open-market or private trades; awards, option exercises, tax withholding and gifts carry other codes.
Recent Form 4 transactions
The 34 most recent of 34 transactions on file: 13 with code P, 0 with code S and 21 with other codes.
| Date | Insider | Title | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 7, 2026 | ORBIMED ADVISORS LLC | Director | C Conversion | 40,000,000 | Not measured | Not measured |
| Aug 7, 2026 | Forbion Growth Opportunities Fund III Cooperatief U.A. | 10% Owner | C Conversion | 7,990,867 | Not measured | Not measured |
| Aug 7, 2026 | Forbion Growth Opportunities Fund III Cooperatief U.A. | 10% Owner | P Purchase | 1,920,000 | $18.00 | $34,560,000 |
| Aug 7, 2026 | Forbion Growth Opportunities Fund III Cooperatief U.A. | 10% Owner | P Purchase | 1,680,000 | $18.00 | $30,240,000 |
| Aug 7, 2026 | Rickey James Paul | Chief Financial Officer | P Purchase | 27,777 | $18.00 | $499,986 |
| Aug 7, 2026 | Viehbacher Christopher | Director | P Purchase | 83,333 | $18.00 | $1,499,994 |
| Aug 7, 2026 | Malek David I | Director | P Purchase | 4,166 | $18.00 | $74,988 |
| Aug 7, 2026 | Anderson Michele A. | Chief Development Officer | P Purchase | 1,111 | $18.00 | $19,998 |
| Aug 7, 2026 | Murdoch Travis | CEO and President | P Purchase | 83,333 | $18.00 | $1,499,994 |
| Aug 7, 2026 | Lubner David Charles | Director | P Purchase | 55,555 | $18.00 | $999,990 |
| Aug 7, 2026 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10% Owner | C Conversion | 7,420,091 | Not measured | Not measured |
| Aug 7, 2026 | AH Bio Fund IV, L.P. | 10% Owner | C Conversion | 9,132,420 | Not measured | Not measured |
| Aug 7, 2026 | AH Bio Fund IV, L.P. | 10% Owner | P Purchase | 1,100,000 | $18.00 | $19,800,000 |
| Aug 7, 2026 | Chimovits Erez | Director | C Conversion | 9,132,420 | Not measured | Not measured |
| Aug 7, 2026 | Chimovits Erez | Director | P Purchase | 1,666,667 | $18.00 | $30,000,006 |
| Aug 7, 2026 | Chimovits Erez | Director | P Purchase | 273,333 | $18.00 | $4,919,994 |
| Aug 7, 2026 | ORBIMED ADVISORS LLC | Director | C Conversion | 9,132,420 | Not measured | Not measured |
| Aug 7, 2026 | ORBIMED ADVISORS LLC | Director | P Purchase | 1,666,667 | $18.00 | $30,000,006 |
| Aug 7, 2026 | ORBIMED ADVISORS LLC | Director | P Purchase | 273,333 | $18.00 | $4,919,994 |
| Aug 7, 2026 | Forbion Growth Opportunities Fund III Cooperatief U.A. | 10% Owner | C Conversion | 40,000,000 | Not measured | Not measured |
| Aug 7, 2026 | Forbion Growth Opportunities Fund III Cooperatief U.A. | 10% Owner | C Conversion | 35,000,000 | Not measured | Not measured |
| Aug 7, 2026 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10% Owner | C Conversion | 32,500,000 | Not measured | Not measured |
| Aug 7, 2026 | AH Bio Fund IV, L.P. | 10% Owner | C Conversion | 40,000,000 | Not measured | Not measured |
| Aug 7, 2026 | Chimovits Erez | Director | C Conversion | 40,000,000 | Not measured | Not measured |
| Aug 7, 2026 | Forbion Growth Opportunities Fund III Cooperatief U.A. | 10% Owner | C Conversion | 9,132,420 | Not measured | Not measured |
| Aug 5, 2026 | Viehbacher Christopher | Director | A Award | 30,000 | Not measured | Not measured |
| Aug 5, 2026 | Malek David I | Director | A Award | 30,000 | Not measured | Not measured |
| Aug 5, 2026 | Anderson Michele A. | Chief Development Officer | A Award | 300,000 | Not measured | Not measured |
| Aug 5, 2026 | Bos Jasper | Director | A Award | 30,000 | Not measured | Not measured |
| Aug 5, 2026 | Murdoch Travis | CEO and President | A Award | 550,000 | Not measured | Not measured |
| Aug 5, 2026 | Lubner David Charles | Director | A Award | 60,000 | Not measured | Not measured |
| Aug 5, 2026 | Rickey James Paul | Chief Financial Officer | A Award | 300,000 | Not measured | Not measured |
| Aug 5, 2026 | Lohoff Tim | Director | A Award | 30,000 | Not measured | Not measured |
| Aug 5, 2026 | Chimovits Erez | Director | A Award | 30,000 | Not measured | Not measured |
Questions about this data
Which insider transactions are open-market trades?
Code P (open market or private purchase) and code S (open market or private sale). Code F is shares withheld to pay tax on vesting stock, A is an award from the company, M and X are option exercises and G is a gift. None of those is the insider choosing to buy or sell in the market.
How quickly are insider trades reported?
A Form 4 is due before the end of the second business day after the trade. The date shown is the transaction date from the form.
Who has to file Form 4?
Officers, directors and beneficial owners of more than 10% of a class of the company’s registered equity, under Section 16 of the Securities Exchange Act.
Look up any code in the Form 4 transaction code reference, or read Form 4 codes explained.